Hongmei Yi

机构：Shanghai Jiao Tong University, Ruijin Hospital, Shanghai Institute of Hematology · ORCID：0000-0002-2054-6401

发表论文 81 篇 · 总被引 1010 次 · h-index 17

代表论文

• Practical microenvironment classification in diffuse large B cell lymphoma using digital pathology (2025 · Cell Reports Medicine · 被引 8)
• A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma (2025 · Blood · 被引 5)
• The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma (2025 · Blood · 被引 4)
• Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study (2025 · Clinical and Translational Medicine · 被引 4)
• A prognostic index integrating deep learning baseline PET/CT biomarkers and multi-omics profiling in diffuse large B cell lymphoma (2025 · Cell Reports Medicine · 被引 3)
• Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study (2025 · Haematologica · 被引 3)